These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 18687492)

  • 21. Severe symptomatic hyponatremia during sibutramine therapy: a case report.
    Esposito P; Rampino T; Gregorini M; Soccio G; Piotti G; Bedino G; Balenzano CT; Roscini E; Cosmai L; Portalupi V; Libetta C; Dal Canton A
    Am J Kidney Dis; 2008 Jul; 52(1):137-9. PubMed ID: 18487000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study.
    Tyczynski JE; Oleske DM; Klingman D; Ferrufino CP; Lee WC
    Drug Saf; 2012 Aug; 35(8):629-44. PubMed ID: 22788234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major adverse cardiac event predictors in survivors of myocardial infarction with asymptomatic left ventricular dysfunction or chronic heart failure.
    Kuch M; Janiszewski M; Mamcarz A; Cudnoch-Jedrzejewska A; Dłuzniewski M
    Med Sci Monit; 2009 Jun; 15(6):PH40-8. PubMed ID: 19478711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Acute myocardial infarction related to cocaine use].
    Batalla Celorio A; Iglesias Cubero G; Rodríguez Reguero JJ; Díaz Molina B; Mayordomo López J
    An Med Interna; 1999 Apr; 16(4):189-90. PubMed ID: 10339845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z; Placha G
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Croatian experience with sibutramine in the treatment of obesity--multicenter prospective study.
    Stimac D; Ruzić A; Majanović SK
    Coll Antropol; 2004 Jun; 28(1):215-21. PubMed ID: 15636078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ; Wilton LV; Shakir SA
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials.
    Kim SH; Lee YM; Jee SH; Nam CM
    Obes Res; 2003 Sep; 11(9):1116-23. PubMed ID: 12972682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurochemical, neuroautonomic and neuropharmacological acute effects of sibutramine in healthy subjects.
    Lechin F; van der Dijs B; Hernandez G; Orozco B; Rodriguez S; Baez S
    Neurotoxicology; 2006 Mar; 27(2):184-91. PubMed ID: 16269176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects.
    Heusser K; Tank J; Diedrich A; Engeli S; Klaua S; Krüger N; Strauss A; Stoffels G; Luft FC; Jordan J
    Clin Pharmacol Ther; 2006 May; 79(5):500-8. PubMed ID: 16678551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
    Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
    Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute myocardial infarction after sumatriptan administration for cluster headache.
    Anghileri E; Toso V; Perini F
    Neurol Sci; 2006 Feb; 26(6):456-9. PubMed ID: 16601942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation.
    Lee J; Teoh T; Lee TS
    J Psychosom Res; 2008 Jan; 64(1):107-9. PubMed ID: 18158006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sustained weight reduction after cessation of obesity treatment with Sibutramine].
    Wirth A
    Dtsch Med Wochenschr; 2004 Apr; 129(18):1002-5. PubMed ID: 15131746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Severe anterior myocardial infarction caused by amphetamine abuse].
    Zebis LP; Christensen TD; Bøttcher M; Eiskjaer HE; Lorenzen AG; Ilkjaer LB; Baandrup U
    Ugeskr Laeger; 2007 Jan; 169(5):423-4. PubMed ID: 17280637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular effects of sibutramine.
    Pisarik P
    Pediatrics; 2007 Oct; 120(4):930-1; author reply 931-2. PubMed ID: 17908786
    [No Abstract]   [Full Text] [Related]  

  • 39. Suicide Attempt in a Patient with Sibutramine Associated Psychosis.
    Câmara Pestana P; Ferreira C; Santos AL; Jerónimo J; Ganança L
    Acta Med Port; 2022 Mar; 35(3):216-218. PubMed ID: 33945464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Withdrawal of sibutramine. Magic bullets now uncontrolled.
    Garrow JS
    BMJ; 2010 Mar; 340():c1351. PubMed ID: 20219800
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.